Uncovering and Dissecting the Genotoxicity of Self-inactivating Lentiviral Vectors In Vivo-Reference-Cited by-同舟云学术

Uncovering and Dissecting the Genotoxicity of Self-inactivating Lentiviral Vectors In Vivo

Published:2014-04 Issue:4 Volume:22 Page:774-785
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Cesana Daniela,Ranzani Marco,Volpin Monica,Bartholomae Cynthia,Duros Caroline,Artus Alexandre,Merella Stefania,Benedicenti Fabrizio,Sergi Sergi Lucia,Sanvito Francesca,Brombin Chiara,Nonis Alessandro,Serio Clelia Di,Doglioni Claudio,von Kalle Christof,Schmidt Manfred,Cohen-Haguenauer Odile,Naldini Luigi,Montini Eugenio

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference50 articles.

1. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy;Montini;J Clin Invest,2009

2. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration;Montini;Nat Biotechnol,2006

3. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors;Modlich;Mol Ther,2009

4. Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region;Arumugam;Mol Ther,2009

5. Physiological promoters reduce the genotoxic risk of integrating gene vectors;Zychlinski;Mol Ther,2008

Cited by 149 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?;International Journal of Molecular Sciences;2024-09-01

2. Improving the Assessment of Risk Factors Relevant to Potential Carcinogenicity of Gene Therapies: A Consensus Article;Human Gene Therapy;2024-08-01

3. Engineering strategies to safely drive CAR T-cells into the future;Frontiers in Immunology;2024-06-19

4. Exploring precision treatments in immune‐mediated inflammatory diseases: Harnessing the infinite potential of nucleic acid delivery;Exploration;2024-05-24

5. Non-clinical safety assessment of novel drug modalities: Genome safety perspectives on viral-, nuclease- and nucleotide-based gene therapies;Mutation Research - Genetic Toxicology and Environmental Mutagenesis;2024-05